Related Experiment Video
Updated: Feb 13, 2026

The Colon-26 Carcinoma Tumor-bearing Mouse as a Model for the Study of Cancer Cachexia
Published on: November 30, 2016
Clinical study on thalidomide combined with cinobufagin to treat lung cancer cachexia
Mingzhi Xie1, Xiaoju Chen1, Shouming Qin2
1Department of Medical Oncology, The Affiliated Tumor Hospital of Guangxi Medical University, Nanning 530021, China.
Objective:
To discuss and assess the clinical value of treating lung cancer cachexia with thalidomide combined with cinobufagin.s.
Methods:
A cohort of 54 patients, who were diagnosed with lung carcinoma, was randomly divided into two groups, a trial group and a control group, respectively. The trial group was given 150 mg/day thalidomide and 2700 mg/day cinobufagin; the control group only received 2,700 mg/day cinobufagin. The therapy lasted for 12 weeks, and the nutritional status, quality of life, survival, and side effects in patients in the two groups were recorded.
Results:
The nutritional status, quality of life, and survival of patients with lung cancer cachexia in the trial group were significantly improved compared to the control group. The trial group received 150 mg thalidomide, which by contrast reduced the incidence of side effect and increased tolerance.
Conclusion:
Using thalidomide combined with cinobufagin to treat patients with lung cancer cachexia will significantly improve their nutritional status and quality of life. This therapy is better than that using cinobufagin alone and is well tolerated.
Related Concept Videos
Lung Capacity
Aneurysm II: Clinical Manifestations and Diagnostic Studies
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
Hypertension III: Clinical Manifestations and Diagnostic Studies
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

